RxDoctor Payments Data

Nicholas Barber, MD

Hematology & Oncology · Salem, ORNPI 1508033465

Payments from drug & device makers

$1,226in general payments, 2019–2025

Across 59 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$181
  • Astellas Pharma US Inc$178
  • Merck$108
  • Novartis$107
  • AVEO Pharmaceuticals, Inc.$68
  • Sanofi$66
  • plus $518 from 20 others

What the payments were for

  • Food & beverage$1,09890%
  • Education$12810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,226 in reported general payments places this provider in the 40th percentile of 112 hematology & oncology providers in Oregon.

See all hematology & oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$2,958,206
Medicare patients
405
Services billed
136,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib44$715,550
Lenalidomide29$501,331
CalquenceAcalabrutinib Maleate32$407,445
XtandiEnzalutamide21$293,361
BrukinsaZanubrutinib15$213,383
VenclextaVenetoclax25$200,052
IbrancePalbociclib13$183,753
EliquisApixaban63$53,559
PegasysPeginterferon Alfa-2a13$49,543
Abiraterone Acetate24$5,745
Anastrozole113$2,846
Tamoxifen Citrate49$1,405
Hydroxyurea21$678
Acyclovir40$485
Oxycodone Hcl48$480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$15$715,55044 claims
AstraZenecaCalquence$27$407,44532 claims
Astellas Pharma US IncXtandi$178$293,36121 claims
PfizerIbrance, Eliquis$44$237,31276 claims
AbbVieVenclexta$18$200,05225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 112 hematology & oncology providers in Oregon.

Other hematology & oncology in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →